Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRC105 + Sorafenib in HCC
NCT01306058Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2011
- Primary completion
- Jun 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of carotuximab in hepatocellular carcinoma (HCC), sponsored by National Cancer Institute. Started Feb 2011; status: completed.
02
Drugs
carotuximab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01306058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01306058.